ArticleRadiology2014
Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival.
Article in Radiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 103 citations in OpenAlex.
- [Focus on molecular imaging in prostate cancer].Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologiePooled it
- Reproducibility and Repeatability of SemiquantitativeJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Trial
- Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study.Radiology · 2017Trial
- Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016Trial
- Atypical adult chronic non-bacterial osteomyelitis (CNO) in skull.EJNMMI reports · 2026Article
- Navigating discordant findings in multimodality imaging of prostate cancer in the MRI and PSMA-PET era.La Radiologia medica · 2026Review
- Prostate Cancer Imaging Beyond PSMA: Applications of GRPR, AR, and Amino Acid Tracers.Diagnostics (Basel, Switzerland) · 2025Review
- Targeting the tumour cell surface in advanced prostate cancer.Nature reviews. Urology · 2025Review
- Androgen receptor as a potential therapeutic target in castration-resistant prostate cancer: a bibliometric analysis (2005-2024).Discover oncology · 2025Article
- Advancements in molecular imaging probes for precision diagnosis and treatment of prostate cancer.Journal of Zhejiang University. Science. B · 2025Review
- A Case of Success: Complete Response to Radium-223 in Metastatic Castration-Resistant Prostate Cancer.Cureus · 2024Article
- [Diagnostics (Basel, Switzerland) · 2023Review
- Androgen Receptor Imaging in the Management of Hormone-Dependent Cancers with Emphasis on Prostate Cancer.International journal of molecular sciences · 2023Review
- Targeted Molecular Imaging as a Biomarker in Urologic Oncology.The Urologic clinics of North America · 2023Review
- Nuclear Receptor Imaging In Vivo-Clinical and Research Advances.Journal of the Endocrine Society · 2023Review
- The Impact of PIK3R1 Mutations and Insulin-PI3K-Glycolytic Pathway Regulation in Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Spine Pain and Metastatic Prostate Cancer: Defining the Contribution of Nonmalignant Etiologies.JCO oncology practice · 2022Article
- Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends.Cancers · 2021Review
- Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review.Journal of clinical medicine · 2021Review
- Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
Corrections and comments
- Commented on by
- Commented on byResponse.2015
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
purposeTo compare the features of bone metastases at computed tomography (CT) to tracer uptake at fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) and fluorine 18 16β-fluoro-5-dihydrotestosterone (FDHT) PET and to determine associations between these imaging features and overall survival in men with castration-resistant prostate cancer. MATERIALS AND
methodsThis is a retrospective study of 38 patients with castration-resistant prostate cancer. Two readers independently evaluated CT, FDG PET, and FDHT PET features of bone metastases. Associations between imaging findings and overall survival were determined by using univariate Cox proportional hazards regression.
resultsIn 38 patients, reader 1 detected 881 lesions and reader 2 detected 867 lesions. Attenuation coefficients at CT correlated inversely with FDG (reader 1: r = -0.3007; P < .001; reader 2: r = -0.3147; P < .001) and FDHT (reader 1: r = -0.2680; P = .001; reader 2: r = -0.3656; P < .001) uptake. The number of lesions on CT scans was significantly associated with overall survival (reader 1: hazard ratio [HR], 1.025; P = .05; reader 2: HR, 1.021; P = .04). The numbers of lesions on FDG and FDHT PET scans were significantly associated with overall survival for reader 1 (HR, 1.051-1.109; P < .001) and reader 2 (HR, 1.026-1.082; P ≤ .009). Patients with higher FDHT uptake (lesion with the highest maximum standardized uptake value) had significantly shorter overall survival (reader 1: HR, 1.078; P = .02; reader 2: HR, 1.092; P = .02). FDG uptake intensity was not associated with overall survival (reader 1, P = .65; reader 2, P = .38).
conclusionIn patients with castration-resistant prostate cancer, numbers of bone lesions on CT, FDG PET, and FDHT PET scans and the intensity of FDHT uptake are significantly associated with overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.